Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy

Journal of Gastroenterology

Volumn 46, Issue 5, 2011, Pages 612-619

  Iijima, Katsunori ^a   Ara, Nobuyuki ^a   Abe, Yasuhiko ^a   Koike, Tomoyuki ^a   Iwai, Wataru ^a   Uno, Kaname ^a   Asano, Naoki ^a   Imatani, Akira ^a   Ohara, Shuichi ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspirin; Gastric acid secretion; Gastric mucosal injury; H. pylori

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; GASTRIN; UNCLASSIFIED DRUG;

AGED; ANGINA PECTORIS; ARTERIOSCLEROSIS; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOSCOPIC GASTRIN TEST; ENTERIC COATED TABLET; FUNCTION TEST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; INJURY SEVERITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY MECHANISM; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH MUCOSA INJURY;

AGED; ASPIRIN; ENDOSCOPY, GASTROINTESTINAL; FIBRINOLYTIC AGENTS; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH DISEASES;

EID: 79958772679     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0385-y     Document Type: Article

References (47)

1. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-30.
2. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-7.
3. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795-801. (Pubitemid 41564359)
4. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16:1945-53.
5. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther. 2009;30:517-31 (Review).
6. Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther. 2007;26:95-106. (Pubitemid 46889838)
7. Rowe PH, Starlinger MJ, Kasdon E, Hollands MJ, Silen W. Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. Gastroenterology. 1987;93:863-71. (Pubitemid 17156014)
8. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996;23:432-4. (Pubitemid 26171549)
9. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-8. (Pubitemid 34680594)
10. Lanas A, Rodrigo L, Márquez JL, Bajador E, Pérez-Roldan F, Cabrol J, EMPHASYS Study Group, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003;38:693-700. (Pubitemid 36920489)
11. Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465-73.
12. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-86. (Pubitemid 34407526)
13. Feldman M, Cryer B, Mallat D, Go MF. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol. 2001;96:1751-7.
14. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a casecontrol study. Gastroenterology. 1999;116:1305-9. (Pubitemid 29258878)
15. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of Helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med. 2004;116:601-5. (Pubitemid 38490534)
16. Hart J, Hawkey CJ, Lanas A, Naesdal J, Talley NJ, Thomson AB, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2010;31:143-9.
17. Wu CY, Poon SK, Chen GH, et al. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol. 1999;34:234-7. (Pubitemid 29192992)
18. Stack WA, Atherton JC, Hawkey GM, Chang CS, Yeh HZ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002;16:497-506. (Pubitemid 34214529)
19. Santolaria S, Lanas A, Benito R, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther. 1999;13:1511-8. (Pubitemid 29516265)
20. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E, Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther. 2001;15:1593-601.
21. Cullen DJ, Hawkey GM, Greenwood DC, Humphreys H, Shepherd V, Logan RF, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal antiinflammatory drugs. Gut. 1997;41:459-62. (Pubitemid 27448775)
22. Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol. 1991;86:735-7.
23. Graham DY, Lidsky MD, Cox AM, Evans DJ Jr, Evans DG, Alpert L, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991;100:1653-7.
24. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32:831-9.
25. McColl KE, el-Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000;29:687-703 (viii. Review).
26. Iijima K, Ohara S, Sekine H, Koike T, Kato K, Asaki S, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut. 2000;46:20-6. (Pubitemid 30307671)
27. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxeninduced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci. 1990;35:1494-9.
28. Naito Y, Iinuma S, Yagi N, Boku Y, Imamoto E, Takagi T, et al. Prevention of indomethacin-induced gastric mucosal injury in Helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine. J Clin Biochem Nutr. 2008;43:34-40.
29. Iijima K, Ohara S, Sekine H, Koike T, Kubota Y, Kato K, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol. 1998;93:2113-8. (Pubitemid 29076860)
30. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther. 2004;19:1181-8. (Pubitemid 38746261)
31. Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2006;15:1341-7. (Pubitemid 44125292)
32. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87-97.
33. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med. 1986;104:390-8 (Review).
34. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17-25. (Pubitemid 29297615)
35. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127:395-402. (Pubitemid 39091887)
36. Nema H, Kato M, Katsurada T, Nozaki Y, Yotsukura A, Yoshida I, et al. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease. J Clin Gastroenterol. 2009;43:130-2.
37. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of lowdose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther. 2000;14:529-34. (Pubitemid 30240743)
38. Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500-7.
39. Iijima K, Ohara S, Koike T, Sekine H, Shimosegawa T. Gastric acid secretion of normal Japanese subjects in relation to Helicobacter pylori infection, aging, and gender. Scand J Gastroenterol. 2004;39:709-16. (Pubitemid 39093242)
40. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci. 1983;28:1-6. (Pubitemid 13223395)
41. Brzozowski T, Konturek PC, Konturek SJ, Ernst H, Stachura J, Hahn EG. Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats. Gut. 1995;37:749-57.
42. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.
43. Baron JH. Studies of basal and peak acid output with an augmented histamine test. Gut. 1963;4:136-44.
44. Ono S, Fujishiro M, Hirano K, Niimi K, Goto O, Kodashima S, et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol. 2009;44(12):1185-9.
45. Ogoshi K, Kaneko E, Tada M, et al. The management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastroenterol Endosc. 2005;47:2691-5.
46. Wilcox MH, Dent TH, Hunter JO, Gray JJ, Brown DF, Wight DG, et al. Accuracy of serology for the diagnosis of Helicobacter pylori infection - a comparison of eight kits. J Clin Pathol. 1996;49:373-6. (Pubitemid 26176786)
47. Shiotani A, Sakakibara T, Yamanaka Y, Nishi R, Imamura H, Fujita M, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol. 2009;44:717-25.